US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Lunai Bioworks

2.28

-0.0950-4.01%

Post-market: 2.280.00000.00%19:46 EDT

Volume:30.42K

Turnover:69.82K

Market Cap:10.31M

PE:-0.04

High:2.42

Open:2.38

Low:2.25

Close:2.37

52wk High:19.60

52wk Low:1.21

Shares:4.53M

Float Shares:2.92M

Volume Ratio:0.80

T/O Rate:1.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-61.5200

EPS(LYR):-86.2743

ROE:-325.46%

ROA:-9.65%

PB:-1.08

PE(LYR):-0.03

Loading ...

Overview Company News Filings

Lunai Bioworks, Inc. Announces Reverse Stock Split

THOMSON REUTERS

Lunai Bioworks Inc. - Common Stock Q3 EPS $(0.10), Sales $20.942K

Benzinga Earnings

Lunai Bioworks Q3 FY26 net loss widens to $2.57 million; revenue $20,942

Lunai Bioworks Inc - Approves Reverse Stock Split at Ratio of 1-for-3 to 1-for-30 - SEC Filing

THOMSON REUTERS

Lunai Bioworks shareholders approved reverse stock split amendment at special meeting

Lunai Bioworks amends 8-K to disclose Nasdaq MVLS noncompliance delisting basis

Lunai Bioworks completes $20 million preferred stock issuance in private placement

Press Release: Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

Lunai Bioworks completes Neurobridge IP Holdings merger, issues $20 million preferred stock

Stock Market Today: Dow Jones, S&P 500 Futures Edge Lower Amid Extension Of Israel-Lebanon Ceasefire—Intel, SAP, Lunai Bioworks In Focus

Benzinga Earnings

Lunai Bioworks unit BioSymetrics signs LOI with Geneial on rare disease cohorts

Lunai Bioworks unit BioSymetrics wins first revenue-generating defense collaboration

Lunai Bioworks (Nasdaq: Lnai) Secures First Revenue-Generating Defense Collaboration Through Biosymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion

THOMSON REUTERS

Lunai Bioworks acquires Clemann Group BBB delivery platform in $20M deal

Lunai Bioworks acquires Clemann Group BBB delivery technology and CNS Alzheimer’s assets; deal totals $20 million at $1.50 conversion price

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring Bbb Delivery Platform for CNS Alzheimer's Therapies With Broad CNS Delivery Applications

THOMSON REUTERS

Lunai Bioworks announces formation of Pathfinder Consortium

Lunai Bioworks launches Pathfinder Consortium to develop chemical countermeasures in 36 months

Tivic Subsidiary Velocity Bioworks Signs San Antonio Facility Leases

BRIEF-Lunai Bioworks Implements Temporary Furlough Of Employees In US And Canada- SEC Filing

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/LNAI/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LNAI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LNAI\",,,,,undefined,":{"symbol":"LNAI","market":"US","secType":"STK","nameCN":"Lunai Bioworks","latestPrice":2.275,"timestamp":1788206400000,"preClose":2.37,"halted":0,"volume":30422,"hourTrading":{"tag":"盘后","latestPrice":2.275,"preClose":2.275,"latestTime":"19:46 EDT","volume":251,"amount":574.44,"timestamp":1788219988389,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.04008438818565409,"floatShares":2922000,"shares":4533900,"eps":-61.52,"marketStatus":"Not Yet Opened","change":-0.095,"latestTime":"08-31 16:00:00 EDT","open":2.375,"high":2.42,"low":2.25,"amount":69819.5152214,"amplitude":0.07173,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-61.52,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":2.37,"preHourTrading":{"tag":"盘前","latestPrice":2.37,"preClose":2.37,"latestTime":"07:00 EDT","volume":607,"amount":1432.867204,"timestamp":1788174011577,"change":0,"changeRate":0,"amplitude":0.004219},"postHourTrading":{"tag":"盘后","latestPrice":2.275,"preClose":2.275,"latestTime":"19:46 EDT","volume":251,"amount":574.44,"timestamp":1788219988389,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.799918,"impliedVol":1.4337,"impliedVolPercentile":0.85},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LNAI\",,,,,undefined,":{"symbol":"LNAI","floatShares":2922000,"roa":"-9.65%","roe":"-325.46%","lyrEps":-86.274256,"volumeRatio":0.799918,"shares":4533900,"dividePrice":0,"high":2.42,"amplitude":0.07173,"preClose":2.37,"low":2.25,"week52Low":1.2104,"pbRate":"-1.08","psRate":"492.53","week52High":19.6,"institutionHeld":0,"latestPrice":2.275,"eps":-61.52,"divideRate":0,"volume":30422,"delay":0,"ttmEps":-61.52,"open":2.375,"prevYearClose":7.0536,"prevWeekClose":2.37,"prevMonthClose":1.94,"prevQuarterClose":3.27,"fiveDayClose":2.13,"twentyDayClose":2.39,"sixtyDayClose":2.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LNAI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-22","symbol":"LNAI","defaultRemindTime":1779456600000,"type":"split","dateTimestamp":1779422400000,"forFactor":8,"toFactor":1,"ratio":8},{"market":"US","date":"2026-05-15","symbol":"LNAI","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.1},{"market":"US","date":"2026-02-17","symbol":"LNAI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1771304400000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2025-11-14","symbol":"LNAI","fiscalQuarterEnding":"2025/09","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":0.13},{"market":"US","date":"2025-09-30","symbol":"LNAI","defaultRemindTime":1759239000000,"type":"split","dateTimestamp":1759204800000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LNAI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LNAI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LNAI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LNAI","date":"2026-08-28","current":-0.036908,"percent":0.738938,"low":-0.265446,"twenty":-0.162557,"median":-0.105321,"eighty":-0.079211,"high":-0.035532,"avg":-0.119516,"sd":0.047177,"marketCap":10654639},"quantilePoints":[{"date":"2025-10-03","current":-0.160171,"twenty":-0.164877,"median":-0.163112,"eighty":-0.161348,"marketCap":28511703},{"date":"2025-10-10","current":-0.161474,"twenty":-0.165919,"median":-0.164078,"eighty":-0.161474,"marketCap":28743506},{"date":"2025-10-17","current":-0.158869,"twenty":-0.16512,"median":-0.161474,"eighty":-0.158869,"marketCap":28279901},{"date":"2025-10-24","current":-0.135429,"twenty":-0.16512,"median":-0.160171,"eighty":-0.152098,"marketCap":24107456},{"date":"2025-10-31","current":-0.122514,"twenty":-0.163557,"median":-0.158218,"eighty":-0.135687,"marketCap":21808324},{"date":"2025-11-07","current":-0.132813,"twenty":-0.161474,"median":-0.152344,"eighty":-0.130739,"marketCap":23641716},{"date":"2025-11-14","current":-0.134115,"twenty":-0.161474,"median":-0.143888,"eighty":-0.121701,"marketCap":23873497},{"date":"2025-11-21","current":-0.254829,"twenty":-0.163557,"median":-0.147149,"eighty":-0.123011,"marketCap":33376540},{"date":"2025-11-28","current":-0.211108,"twenty":-0.166054,"median":-0.152344,"eighty":-0.125001,"marketCap":27650221},{"date":"2025-12-05","current":-0.232577,"twenty":-0.211108,"median":-0.158218,"eighty":-0.130221,"marketCap":30462108},{"date":"2025-12-12","current":-0.20753,"twenty":-0.221843,"median":-0.160171,"eighty":-0.132813,"marketCap":27181573},{"date":"2025-12-19","current":-0.184259,"twenty":-0.212897,"median":-0.161474,"eighty":-0.134115,"marketCap":24133572},{"date":"2025-12-26","current":-0.176388,"twenty":-0.211466,"median":-0.164729,"eighty":-0.134115,"marketCap":23102623},{"date":"2026-01-02","current":-0.157729,"twenty":-0.211108,"median":-0.164729,"eighty":-0.134896,"marketCap":20658806},{"date":"2026-01-09","current":-0.162828,"twenty":-0.208961,"median":-0.16538,"eighty":-0.135424,"marketCap":21326580},{"date":"2026-01-16","current":-0.16442,"twenty":-0.206179,"median":-0.165717,"eighty":-0.136203,"marketCap":21535113},{"date":"2026-01-23","current":-0.164223,"twenty":-0.200455,"median":-0.16538,"eighty":-0.13724,"marketCap":21509339},{"date":"2026-01-30","current":-0.150287,"twenty":-0.192502,"median":-0.16442,"eighty":-0.139063,"marketCap":19684091},{"date":"2026-02-06","current":-0.115725,"twenty":-0.190708,"median":-0.163453,"eighty":-0.135462,"marketCap":15157289},{"date":"2026-02-13","current":-0.146316,"twenty":-0.189626,"median":-0.161474,"eighty":-0.135462,"marketCap":19163931},{"date":"2026-02-20","current":-0.111222,"twenty":-0.189268,"median":-0.161474,"eighty":-0.134115,"marketCap":13960941},{"date":"2026-02-27","current":-0.077077,"twenty":-0.187121,"median":-0.158869,"eighty":-0.128849,"marketCap":9674942},{"date":"2026-03-06","current":-0.069658,"twenty":-0.184259,"median":-0.157729,"eighty":-0.122516,"marketCap":8743729},{"date":"2026-03-13","current":-0.037035,"twenty":-0.183139,"median":-0.156666,"eighty":-0.116398,"marketCap":4648809},{"date":"2026-03-20","current":-0.074186,"twenty":-0.178206,"median":-0.153221,"eighty":-0.113305,"marketCap":9312132},{"date":"2026-03-27","current":-0.095113,"twenty":-0.176388,"median":-0.150672,"eighty":-0.107552,"marketCap":11938878},{"date":"2026-04-02","current":-0.079389,"twenty":-0.176388,"median":-0.150189,"eighty":-0.092492,"marketCap":9965190},{"date":"2026-04-10","current":-0.079794,"twenty":-0.175994,"median":-0.147149,"eighty":-0.079794,"marketCap":10015984},{"date":"2026-04-17","current":-0.058578,"twenty":-0.173812,"median":-0.143919,"eighty":-0.0791,"marketCap":7352956},{"date":"2026-04-24","current":-0.088046,"twenty":-0.173794,"median":-0.139607,"eighty":-0.079389,"marketCap":11051809},{"date":"2026-05-01","current":-0.095356,"twenty":-0.173686,"median":-0.136115,"eighty":-0.079543,"marketCap":11969469},{"date":"2026-05-08","current":-0.096223,"twenty":-0.172094,"median":-0.135417,"eighty":-0.079543,"marketCap":12078282},{"date":"2026-05-15","current":-0.079926,"twenty":-0.171736,"median":-0.133464,"eighty":-0.079794,"marketCap":10032591},{"date":"2026-05-22","current":-0.082023,"twenty":-0.169948,"median":-0.130221,"eighty":-0.079389,"marketCap":10522249},{"date":"2026-05-29","current":-0.107441,"twenty":-0.168989,"median":-0.126835,"eighty":-0.079331,"marketCap":13783022},{"date":"2026-06-05","current":-0.1032,"twenty":-0.168377,"median":-0.122519,"eighty":-0.079512,"marketCap":13238955},{"date":"2026-06-12","current":-0.088356,"twenty":-0.168045,"median":-0.119258,"eighty":-0.079543,"marketCap":11334722},{"date":"2026-06-18","current":-0.14137,"twenty":-0.167069,"median":-0.118498,"eighty":-0.079694,"marketCap":18135556},{"date":"2026-06-26","current":-0.12582,"twenty":-0.166216,"median":-0.121361,"eighty":-0.079842,"marketCap":16140644},{"date":"2026-07-02","current":-0.109209,"twenty":-0.16583,"median":-0.118878,"eighty":-0.079874,"marketCap":14009717},{"date":"2026-07-10","current":-0.096485,"twenty":-0.165448,"median":-0.115725,"eighty":-0.079895,"marketCap":12377516},{"date":"2026-07-17","current":-0.101787,"twenty":-0.16538,"median":-0.113965,"eighty":-0.08033,"marketCap":13057600},{"date":"2026-07-24","current":-0.081995,"twenty":-0.165046,"median":-0.113282,"eighty":-0.081349,"marketCap":10518622},{"date":"2026-07-31","current":-0.071392,"twenty":-0.16452,"median":-0.112744,"eighty":-0.079874,"marketCap":9158455},{"date":"2026-08-07","current":-0.085529,"twenty":-0.164381,"median":-0.110215,"eighty":-0.079874,"marketCap":10972011},{"date":"2026-08-14","current":-0.079167,"twenty":-0.164194,"median":-0.108855,"eighty":-0.079874,"marketCap":10155911},{"date":"2026-08-21","current":-0.077754,"twenty":-0.163828,"median":-0.107366,"eighty":-0.079525,"marketCap":9974555},{"date":"2026-08-28","current":-0.083055,"twenty":-0.162557,"median":-0.105321,"eighty":-0.079211,"marketCap":10654639}],"updateTime":1788204778311},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LNAI\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636840663","title":"Lunai Bioworks, Inc. Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2636840663","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636840663?lang=en_us&edition=fundamental","pubTime":"2026-05-20 21:15","pubTimestamp":1779282902,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nTUA4H1RSQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635055865","title":"Lunai Bioworks Inc. - Common Stock Q3 EPS $(0.10), Sales $20.942K","url":"https://stock-news.laohu8.com/highlight/detail?id=2635055865","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635055865?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:19","pubTimestamp":1778883561,"startTime":"0","endTime":"0","summary":"Lunai Bioworks Inc. - Common Stock (NASDAQ:LNAI) reported quarterly losses of $(0.10) per share.  The company reported $20.942 thousand in sales this quarter.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52620268/lunai-bioworks-inc-common-stock-q3-eps-0-10-sales-20-942k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI",".IXIC","TQQQ","QID","MNQmain","QDTE","IYW","PSQ","QLD","SQQQ","JEPQ","FTEC","TECS","QQQA","NVIW.SI","NDX","ONEQ","BK4139","NQmain","QQQY","GPIQ","QQQE","QYLG","QQQM","QQQJ","QQQ","TQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635058308","title":"Lunai Bioworks Q3 FY26 net loss widens to $2.57 million; revenue $20,942","url":"https://stock-news.laohu8.com/highlight/detail?id=2635058308","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635058308?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:50","pubTimestamp":1778878241,"startTime":"0","endTime":"0","summary":"Lunai Bioworks posted a net loss of USD 2.57 million for quarter ended March 31, 2026, swinging from net income of USD 189,176 a year earlier as operating loss narrowed 66% to USD 1.43 million.Revenue was USD 20,942, compared with no revenue a year earlier, while operating expenses fell 65% to USD 1.45 million on a 66% drop in general and administrative costs to USD 1.42 million.Cash and cash equivalents totaled USD 3.16 million at March 31, 2026, up from USD 92,700 at June 30, 2025, while working capital deficit narrowed 45% to USD 15.55 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL9VSRR7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Lunai Bioworks Q3 FY26 net loss widens to $2.57 million; revenue $20,942","news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635756354","title":"Lunai Bioworks Inc - Approves Reverse Stock Split at Ratio of 1-for-3 to 1-for-30 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635756354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635756354?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:51","pubTimestamp":1778705506,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nFWN41Q1IQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635755009","title":"Lunai Bioworks shareholders approved reverse stock split amendment at special meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2635755009","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635755009?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:46","pubTimestamp":1778705194,"startTime":"0","endTime":"0","summary":"Lunai Bioworks held a special shareholder meeting on May 8, 2026.Shareholders authorized an amendment to the certificate of incorporation to allow a reverse stock split, with the ratio to be set by the board within a 1-for-3 to 1-for-30 range.The vote did not confirm the reverse split has been implemented.Investors also backed a measure to adjourn the meeting if needed to seek additional proxies to pass the reverse-split authorization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 13, 2026, and is solely responsible ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLqkQ6k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634157253","title":"Lunai Bioworks amends 8-K to disclose Nasdaq MVLS noncompliance delisting basis","url":"https://stock-news.laohu8.com/highlight/detail?id=2634157253","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634157253?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:31","pubTimestamp":1778535073,"startTime":"0","endTime":"0","summary":"Lunai Bioworks filed an amended Form 8-K to update its earlier report with an additional Nasdaq staff determination letter received April 28, 2026.Letter warned continued failure to meet Nasdaq Listing Rule 5550 market value of listed securities threshold of $35 million, with grace period expiring April 27, 2026, could serve as an additional basis for delisting.Nasdaq Hearings Panel previously granted an exception through May 1, 2026 to regain compliance via stockholders’ equity alternative, with bid-price compliance deadline set for June 1, 2026.Stockholders authorized a reverse stock split range of 1-for-3 to 1-for-30 on May 8, 2026, with company seeking a short extension to meet bid-price rule following a meeting delay.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL6Yn9ph:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632956918","title":"Lunai Bioworks completes $20 million preferred stock issuance in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2632956918","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632956918?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:35","pubTimestamp":1777901723,"startTime":"0","endTime":"0","summary":"The company issued Series B Preferred Stock with an aggregate stated value of $20 million.The funds are intended to support the acquisition of CNS delivery and neurotherapeutic intellectual property.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDLbX1WXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632561729","title":"Press Release: Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP","url":"https://stock-news.laohu8.com/highlight/detail?id=2632561729","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632561729?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:35","pubTimestamp":1777901700,"startTime":"0","endTime":"0","summary":"Transaction Adds Dual BBB Delivery Strategies, Supports Alzheimer's Programs, Combination Therapies, 505 Pathways, and CNS Countermeasure Applications. The acquired intellectual property expands Lunai's ability to connect therapeutic discovery with delivery, supporting a more integrated approach to CNS drug development. By pairing compound design with delivery optimization, the Company is advancing a framework aimed at increasing drug concentration in the brain while reducing systemic exposure. This approach addresses both challenges by combining novel neurotherapeutic compounds with complementary delivery technologies, improving CNS access and enabling multi-agent, combinatorial strategies. Together, the portfolio strengthens Lunai's ability not only to deliver therapeutics to the brain, but to develop and deploy both single-agent and combination therapies that target distinct aspects of disease biology. This approach may be applicable across multiple neurological indications as well ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","LU1169589451.USD","BK4585","IE00B3T34201.USD","BK4588","LU1487256676.USD","BBB","BK4136","IP","LU1169590202.USD","LNAI","LU1481600234.SGD","BK4139","BK4135","LU1481599808.USD","LU2463526074.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632628317","title":"Lunai Bioworks completes Neurobridge IP Holdings merger, issues $20 million preferred stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2632628317","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632628317?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:18","pubTimestamp":1777670286,"startTime":"0","endTime":"0","summary":"Lunai Bioworks completed merger of Neurobridge IP Holdings into its wholly owned subsidiary Lunai Bioworks IP on May 1, 2026.Transaction transferred a multi-jurisdictional patent portfolio into Lunai structure.Consideration consisted of 8 shares of Series B Convertible Preferred Stock with aggregate stated value of $20 million.Oncotelic received 5 Series B shares with stated value of $12.5 million.Pelerin Therapeutics received 3 Series B shares with stated value of $7.5 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission ,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL900ZLp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629145638","title":"Stock Market Today: Dow Jones, S&P 500 Futures Edge Lower Amid Extension Of Israel-Lebanon Ceasefire—Intel, SAP, Lunai Bioworks In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2629145638","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629145638?lang=en_us&edition=fundamental","pubTime":"2026-04-24 17:31","pubTimestamp":1777023061,"startTime":"0","endTime":"0","summary":"U.S. stock futures were mixed on Friday following Thursday&#39;s decline, after President Donald Trump announced the extension of the ceasefire between Israel and Lebanon by three weeks.\n\n\n\nOn Thursday, the Dow Jones index closed 179 points lower as investors gauged the evolving Middle East conflict and a downturn in the software sector.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/04/52023332/stock-market-today-dow-jones-sp-500-futures-edge-lower-amid-extension-of-israel-lebanon-ceasefire-intel-sap-lunai-bioworks-in-focus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","JEPI","LU0096364046.USD","LU1066053197.SGD","SPYG","IE00B1XK9C88.USD","IJH","LU0098860793.USD","SPXL","LU0321505868.SGD","SFY","LU0097036916.USD","LU1430594728.SGD","LU2242652126.USD","LU2552382132.HKD","LU0320765646.SGD","LU0237698245.USD","SAP","LU2931357623.SGD","BK4515","INTC","LU0081259029.USD","VBK","LU1585245621.USD","SG9999015341.SGD","IVW","LU1162221912.USD","NOBL","SG9999002224.SGD","LU0689626769.HKD","LU1066051498.USD","SDS","LU2129689514.USD","SPYI","LU0640476718.USD","HIBS","LU0124676726.USD","GSLC","LNAI","BK4567","LU1914381329.SGD","LU2148611432.USD","BK4581","LU2552382215.SGD","SG9999014542.SGD","SPHQ","SPYD","BK4512","SPYM","VTI","BK4529","BMAY","BK4593","LU0094547139.USD","CAST","LU2543165471.USD","04335","LU0274383776.USD","LU1280957306.USD","SPLV","XLG","SPGP","BK4018","INTW","ITOT","BK4141","LU2089985449.USD","BK4108","BK4554","SPUU","IVV","SG9999015358.SGD","BK4612","BK4535","LU2242646821.SGD","BK4585","MOAT","ESmain","VV","HIBL","SSO","LU0868494617.USD","TECL","SPXU","LU1929549753.HKD","BK4613","IE00B3T34201.USD","OEF","BK4533","MESmain","BK4534","OEX","GPIX","LU1868836757.USD","SPYV","RSP","BK4579","IE000M9KFDE8.USD","SG9999001440.SGD","BK4528","LU1868837136.USD","GB00BDT5M118.USD","BK4550","SPUS","SG9999002232.USD","SH","BK4023","IE00BLSP4239.USD","LU0234570918.USD","BK4559","LU1868837300.USD","BK4588","BK4558","SPMO","BK4527","SCHB","BK4602","LU2129689431.USD","DBSC","XDTE","BK4605","LU1868836914.USD","LU2129689605.HKD","LU2552382058.USD","ALLW","BK4575","SPHD","IE00BBT3K403.USD","IE00BKDWB100.SGD","BK4139","IE00BN8TJ469.HKD","LU0321505439.SGD","SPXS","LINT","SPYQ","SPYU","IE00BWXC8680.SGD","IJR","LU0061475181.USD","TSPY","XYLD","VEU","LU0868494708.USD","ACWI","IE00BLSP4452.SGD","LU0234572021.USD","PG","BK4561","LU2097829019.USD","IVE","LU0323591593.USD","ETFT","YSPY","SG9999014575.USD","SPDN","LU1868836591.USD","SG9999014567.USD","SCHX","VTV","BK4543","UPRO","LU0942090050.USD","SG9999014559.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627128759","title":"Lunai Bioworks unit BioSymetrics signs LOI with Geneial on rare disease cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2627128759","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627128759?lang=en_us&edition=fundamental","pubTime":"2026-04-15 21:10","pubTimestamp":1776258650,"startTime":"0","endTime":"0","summary":"Lunai Bioworks unit BioSymetrics signed a non-binding letter of intent with Geneial to pursue a strategic collaboration in rare neurological disorders.Partnership targets creation of trial-ready patient cohorts by integrating patient-led datasets across multiple registries with longitudinal clinical data.Companies aim to use resulting cohorts to support commercial partnerships with pharmaceutical and biotechnology groups, creating potential revenue-generating collaborations.Initial focus covers select rare neurodevelopmental disorders, with plans to expand program scope over time.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL59NqSx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625037953","title":"Lunai Bioworks unit BioSymetrics wins first revenue-generating defense collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2625037953","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625037953?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:06","pubTimestamp":1775567177,"startTime":"0","endTime":"0","summary":"Lunai Bioworks unit BioSymetrics signed a revenue-generating, multi-year commercial defense collaboration with a specialized biotechnology partner to deploy an AI platform for chemical threat assessment.BioSymetrics will use zebrafish-based phenotypic screening with AI-driven mechanism-of-action prediction to identify and classify neuroactive or neurotoxic compounds.Lunai said additional defense-focused engagements are under discussion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via PR Newswire  on April 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL9g3Mty:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953783","title":"Lunai Bioworks (Nasdaq: Lnai) Secures First Revenue-Generating Defense Collaboration Through Biosymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953783","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953783?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:05","pubTimestamp":1775567100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA44DVK1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623324913","title":"Lunai Bioworks acquires Clemann Group BBB delivery platform in $20M deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2623324913","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623324913?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:41","pubTimestamp":1774906916,"startTime":"0","endTime":"0","summary":"Lunai Bioworks executed a binding $20 million transaction to acquire blood-brain barrier delivery technology and CNS Alzheimer’s drug assets from Clemann Group.Consideration uses Series B convertible preferred stock with a fixed $1.50 per-share conversion price.Conversion is subject to a 19.9% beneficial ownership cap.Assets include a delivery platform designed to cross blood-brain barrier, with activation intended to occur inside brain.Acquisition expands Lunai’s CNS pipeline beyond Alzheimer’s into other neurological disorders where brain penetration limits drug development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunai Bioworks Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLnYNhH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622478850","title":"Lunai Bioworks acquires Clemann Group BBB delivery technology and CNS Alzheimer’s assets; deal totals $20 million at $1.50 conversion price","url":"https://stock-news.laohu8.com/highlight/detail?id=2622478850","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622478850?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:51","pubTimestamp":1774529482,"startTime":"0","endTime":"0","summary":"Lunai Bioworks acquires Clemann Group BBB delivery technology and CNS Alzheimer’s assets; deal totals $20 million at $1.50 conversion price. Lunai Bioworks entered a binding strategic transaction valued at USD 20 million to acquire blood-brain barrier delivery technology and CNS Alzheimer’s drug assets from the Clemann Group.The consideration is structured as Series B convertible preferred stock with a fixed conversion price of USD 1.50 per share.The conversion is subject to a 19.9% beneficial ownership limitation.The acquired platform is intended to support delivery of therapeutics into the brain for Alzheimer’s and other CNS indications.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL3fXRpj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622410850","title":"Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring Bbb Delivery Platform for CNS Alzheimer's Therapies With Broad CNS Delivery Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2622410850","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622410850?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:51","pubTimestamp":1774529474,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E0L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620133229","title":"Lunai Bioworks announces formation of Pathfinder Consortium","url":"https://stock-news.laohu8.com/highlight/detail?id=2620133229","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620133229?lang=en_us&edition=fundamental","pubTime":"2026-03-19 22:10","pubTimestamp":1773929431,"startTime":"0","endTime":"0","summary":"Lunai Bioworks (LNAI) announced the formation of a national consortium designed to accelerate the discovery and development of chemical countermeas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lunai-bioworks-announces-formation-of-pathfinder-consortium-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lunai-bioworks-announces-formation-of-pathfinder-consortium-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LNAI","BK4211","PBHC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620226176","title":"Lunai Bioworks launches Pathfinder Consortium to develop chemical countermeasures in 36 months","url":"https://stock-news.laohu8.com/highlight/detail?id=2620226176","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620226176?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:58","pubTimestamp":1773928715,"startTime":"0","endTime":"0","summary":"Lunai Bioworks said its BioSymetrics unit formed the Pathfinder Consortium to coordinate academic, military, and biotech efforts on chemical countermeasure discovery and development.The company described a development model aiming to complete efficacy and safety steps in about 36 months, including a 50-person Phase I safety study.The program includes screening in yeast and cell-based systems, followed by validation in FDA-recognized zebrafish models.Lunai said validated countermeasures are typically procured for U.S. government stockpiling programs ranging from USD 400 million to USD 1.2 billion per program.Named collaborators include Calum MacRae, Vik Bebarta, Randall Peterson, and Vincent Jo Davidson.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3y24gL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619443143","title":"Tivic Subsidiary Velocity Bioworks Signs San Antonio Facility Leases","url":"https://stock-news.laohu8.com/highlight/detail?id=2619443143","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619443143?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:28","pubTimestamp":1773437298,"startTime":"0","endTime":"0","summary":"Tivic Health Systems Inc.’s wholly owned subsidiary Velocity Bioworks, Inc. entered into three facility agreements in San Antonio, Texas. Velocity Bioworks signed an eight-year lease for an 8,024-square-foot microbial facility with an option to extend and an option to purchase the property for $12.5 million within the first 24 months, a 102-month lease for a 20,144-square-foot mammalian facility, and a 110-month sublease for 8,122 square feet of office space that will serve as Tivic’s new principal executive office.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL5Dp1v8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","TIVC","BK4139","LNAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617574329","title":"BRIEF-Lunai Bioworks Implements Temporary Furlough Of Employees In US And Canada- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2617574329","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617574329?lang=en_us&edition=fundamental","pubTime":"2026-03-06 06:19","pubTimestamp":1772749169,"startTime":"0","endTime":"0","summary":"BRIEF-Lunai Bioworks Implements Temporary Furlough Of Employees In US And Canada- SEC FilingMarch 5  - SEC Filing:LUNAI BIOWORKS INC - IMPLEMENTS TEMPORARY FURLOUGH OF EMPLOYEES IN US AND CANADA ON FEB 27, 2026 - SEC FILINGLUNAI BIOWORKS INC - CEO AND CFO VOLUNTARILY AGREE TO TEMPORARILY DEFER SALARY PAYMENTS DURING FURLOUGH - SEC FILINGLUNAI BIOWORKS INC - AFFECTED EMPLOYEES WILL NOT PERFORM SERVICES OR RECEIVE COMPENSATION DURING FURLOUGH - SEC FILINGLUNAI BIOWORKS INC - MAINTAINS LIMITED OPERATIONS AND BEGINS RECALLING SOME OPERATIONAL EMPLOYEES FROM FURLOUGH - SEC FILINGSource text: [ID:n0001731122-26-000345]Further company coverage: LNAI.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT0U2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNAI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":43,"code":"91000000","status":"200"}]}}